186 related articles for article (PubMed ID: 19112964)
1. [ASCO 2008. Bevacizumab in advanced renal carcinoma].
Mansueto G; Longo F
Tumori; 2008; 94(5):15-23. PubMed ID: 19112964
[No Abstract] [Full Text] [Related]
2. Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C; Szczylik C
Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
4. Targeted drugs for metastatic renal cell carcinoma.
Motzer RJ; Basch E
Lancet; 2007 Dec; 370(9605):2071-3. PubMed ID: 18156012
[No Abstract] [Full Text] [Related]
5. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
6. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
7. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
8. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Schmidinger M; Zielinski CC
Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
[TBL] [Abstract][Full Text] [Related]
9. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
10. [Targeted therapies and their indications in solid neoplasias].
Dreyer C; Raymond E; Faivre S
Rev Med Interne; 2009 May; 30(5):416-24. PubMed ID: 19299048
[TBL] [Abstract][Full Text] [Related]
11. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and everolimus in renal cancer: a rational way forward.
Stadler WM; Phillips G; George DJ; Halabi S; Small E
J Clin Oncol; 2010 Nov; 28(33):e692-3; author reply e694. PubMed ID: 20940194
[No Abstract] [Full Text] [Related]
13. Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.
Kruck S; Kuczyk MA; Gakis G; Kramer MW; Stenzl A; Merseburger AS
Rev Recent Clin Trials; 2008 Sep; 3(3):212-6. PubMed ID: 18782079
[TBL] [Abstract][Full Text] [Related]
14. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
15. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
16. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
[No Abstract] [Full Text] [Related]
17. [Systemic therapy of metastasizing renal cell carcinoma].
Staehler M; Haseke N; Zilinberg K; Stadler T; Karl A; Stief CG
Urologe A; 2008 Oct; 47(10):1357-67. PubMed ID: 18825295
[TBL] [Abstract][Full Text] [Related]
18. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
19. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
Escudier B
J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
[No Abstract] [Full Text] [Related]
20. [Targeted therapies: sequential and combined treatments].
Gross-Goupil M; Escudier B
Bull Cancer; 2010; 97():65-71. PubMed ID: 20418205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]